Key facts
- Utilizer’s last known valuation is $4.2M (Dec 2024).
- It has raised $1.5M; the latest was Early Stage VC ($360K) in Dec 2024.
- Notable investors include Almi Invest, Stockholm Innovation & Growth, Propel Capital (Sweden).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Utilizer
- ·The full record, as it builds
Funding rounds
No funding rounds for Utilizer are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Utilizer
Developer of point-of-care diagnostic tests designed to detect and quantify bacterial infections. The company offers miniaturized culture-based dipstick tests with mobile phone readout that measure bacteria in the clinically relevant range without laboratory instruments, enabling non-trained users to identify urinary tract infections at home and primary care settings.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2021
- Employees
- 5
- Website
- utilizer.se/
- Ownership
- Privately Held (backing)
Utilizer doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Utilizer shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Utilizer in its N-PORT filings yet. We sweep new filings monthly.